257 related articles for article (PubMed ID: 30382484)
1. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.
Matuoka JY; Kahn JG; Secoli SR
Eur J Health Econ; 2019 Jun; 20(4):487-499. PubMed ID: 30382484
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Carter JA; Joshi AD; Kaura S; Botteman MF
Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M
J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
Ford J; Cummins E; Sharma P; Elders A; Stewart F; Johnston R; Royle P; Jones R; Mulatero C; Todd R; Mowatt G
Health Technol Assess; 2013 Jul; 17(29):1-386. PubMed ID: 23870108
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
14. Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases.
Koo K; Lam K; Mittmann N; Konski A; Dennis K; Zeng L; Lam H; Chow E
Support Care Cancer; 2013 Jun; 21(6):1785-91. PubMed ID: 23519570
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
Dellis A; Papatsoris A
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):5-10. PubMed ID: 26588857
[TBL] [Abstract][Full Text] [Related]
16. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
[TBL] [Abstract][Full Text] [Related]
18. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Carter JA; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
[TBL] [Abstract][Full Text] [Related]
19. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
